invoX Pharma was incorporated in March 2021 and is a wholly owned subsidiary of Sino Biopharm, a Hong Kong listed, global top 40 pharmaceutical company with more than 24,000 employees. UK-based invoX is an expanding biopharmaceutical company focusing on R&D, Clinical Development and Business Development activities in the UK, EU and US, with a core focus on oncology and respiratory therapeutics.
Our core team is made up of a multicultural international group of highly experienced individuals with life sciences and technology-centred backgrounds, all with a mutual passion and ambition for creating something different.
We aspire to improve people’s lives by creating access to innovative medicine.
To be a leading global pharmaceutical company through delivering innovative therapies for patients.
invoX’s mission by 2026 is to be a globally recognised, fully integrated pharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs.
Integrity: We can be trusted and relied upon to consistently do the right thing
Quality: We hold ourselves to the highest standards in everything we do
Passion: We are passionate in our mission to deliver innovation
Performance: As a team we consistently strive to achieve exceptional results
Well being: We support our employees to achieve their goals in every aspect of their live
We are well on our way, through multiple acquisitions and investments, to create a scalable platform to build a portfolio of promising clinical and pre-clinical stage drug candidates, which we believe will improve people’s lives by creating access to innovative medicine across some of our key therapeutic areas including oncology and respiratory.